We Claim:

1. A compound of Formula I



Formula I

or a pharmaceutically acceptable salt thereof wherein:

A is structure i, ii, iii, or iv;



i ii iii iv

wherein the dashed line in formula iii represents an optional double bond;

n is 0 or 1;

X is O, S, NH, Nalkyl, NOH, and NOalkyl;

Z is $NHC(=O)R^1$, $NHC(=S)R^1$, $C(=O)NHR^1$, C(=O)N(H)OH, $NHC(=NCN)R^1$, NH–het^1, O-het^1, S-het^1, or het^2;

R^1 is H, NH_2, NHC_{1-4}alkyl, C_{1-4}alkyl, C_{2-4}alkenyl, $-(CH_2)_mC(=O)C_{1-4}$alkyl, OC_{1-4}alkyl, SC_{1-4}alkyl, $(CH_2)_mC_{3-6}$cycloalkyl, CH=CH-aryl, CH=CH-het^1, $CH_2C(=O)$-aryl, or $CH_2C(=O)$-het^1, the alkyl, aryl or het optionally being a substituted alkyl, substituted aryl or substituted het, respectively;

R^2 and R^3 are independently H or F;

R^4 is H, Cl, F, CH_3, CF_3, NH_2, NO_2 or CN;

R^5 and R^6 are independently H, alkyl, substituted alkyl, -Salkyl, -Oalkyl, alkenyl, substituted alkenyl, hydroxy, aryl, or halo;

R^7 is H, alkyl, substituted alkyl, cycloalkyl, C(=O)alkyl, C(=O)substituted alkyl, aryl, alkenyl, substituted alkenyl, het, substituted het, or substituted aryl;

het^1 is a C-linked five- (5) or six- (6) membered heterocyclic ring which contains 1-4 heteroatoms selected from oxygen, sulfur, and nitrogen;

het^2 is a N- or C-linked five- (5) or six- (6) membered heterocyclic ring which contains 1-4 heteroatoms selected from oxygen, sulfur, and nitrogen;

each m is independently 0, 1 or 2.

2. The compound of claim 1, wherein A is



i .

3. The compound of claim 1, wherein R_7 is alkyl or substituted alkyl.

4. The compound of claim 1, wherein R_5 is halo.

5. The compound of claim 4, wherein R_6 is halo.

6. The compound of Claim 1 selected from the group:

a) (5*R*)-(-)-3-(3,3-Difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-N-methyl-2-oxo-5-oxazolidinecarboxamide;

b) (5*R*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinecarboxamide;

c) (5*R*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinecarboxamide;

d) (5*R*)-(-)-3-(3,3-Difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-N-methyl-2-oxo-5-oxazolidinecarboxamide;

e) N-[[(5*S*)-(-)-3-(3,3-Difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide; and

f) N-[[(5*S*)-(-)-3-(3,3-Difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide.

7. A compound of Formula II



II

wherein:

R^7 is alkyl of 1 to 4 carbons;

M is selected from the group consisting of NO_2, NH_2, $NHC(O)OR^8$, or structure i



i ;

wherein R^8 is alkyl of 1 to 4 carbons or benzyl.

8. The compound of claim 7, wherein R_7 is alkyl or substituted alkyl.

9. The compound of Claim 7 selected from the group:

a) butyl (5R)-3-(3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinecarboxylate;
b) benzyl 1-ethyl-3,3-difluoro-2-oxo-2,3-dihydro-1H-indol-5-ylcarbamate;
c) 5-amino-1-ethyl-3,3-difluoro-1,3-dihydro-2H-indol-2-one;
d) 1-ethyl-3,3-difluoro-5-nitro-1,3-dihydro-2H-indol-2-one;
e) benzyl 3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1H-indol-5-ylcarbamate;
f) 5-amino-3,3-difluoro-1-methyl-1,3-dihydro-2H-indol-2-one;
g) 3,3-difluoro-1-methyl-5-nitro-1,3-dihydro-2H-indol-2-one; and
h) butyl (5R)-3-(3,3-difluoro-1-ethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-2-oxo-5-oxazolidinecarboxylate.

10. Use of a compound of claim 1 or 7 for preparing a medicament for treating microbial infections in mammals.

11. The use of claim 10, wherein the medicament is prepared for administration orally, parenterally, transdermally, or topically.

12. The use of claim 10, wherein the medicament includes from about 0.1 to about 1000 mg of the compound of claim 1 or 7.

13. The use of claim 10, wherein the medicament includes from about 0.1 to about 500 mg of the compound of claim 1 or 7.

14. A pharmaceutical composition comprising a compound of claim 1 or 7 and a pharmaceutically acceptable carrier.